Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.53 |
| ▸ | HTR3B | O95264 | 3/20 | 0.53 |
| ▸ | HTR3A | P46098 | 3/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29848342 | 1.00 | TAAR1 (0.63) | TAAR1AOC3PNMTHTR3EHTR3B | |
| Ammonia Solution, Strong SCHEMBL3788232 | 0.98 | TAAR1 (0.61) | TAAR1AOC3PNMTHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL28484059 | 0.96 | TAAR1 (0.59) | TAAR1AOC3PNMTHTR3EHTR3B | |
| SCHEMBL27361590 | 0.90 | CHRM2 (0.57) | TAAR1AOC3PNMTHTR3EHTR3B | |
| SCHEMBL4427360 | 0.88 | TAAR1 (0.52) | TAAR1AOC3PNMTHTR3EHTR3B | |
| SCHEMBL197297 | 0.87 | TAAR1 (0.59) | TAAR1AOC3PNMTHTR3EHTR3B | |
| SCHEMBL12050856 | 0.85 | TAAR1 (0.74) | TAAR1AOC3PNMTHTR3EHTR3B | |
| SCHEMBL14047464 | 0.85 | TAAR1 (0.57) | TAAR1AOC3PNMTHTR3EHTR3B | |
| SCHEMBL24244205 | 0.84 | LPL (0.57) | TAAR1AOC3HTR3EHTR3BHTR3A | |
| SCHEMBL28525346 | 0.84 | LPL (0.57) | TAAR1AOC3HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12406696-B2 | Photopolymer compositions for thermostable photopolymers in the visible spectral range | COVESTRO DEUTSCHLAND AG (DE) | 2025-09-02 | — | — | US | disclosed |
| US-20250182787-A1 | Photopolymer Compositions for Thermostable Photopolymers in the Visible Spectral Range | COVESTRO DEUTSCHLAND AG (DE) | 2025-06-05 | — | — | US | disclosed |
| US-20250171648-A1 | Thermostable Photopolymers in the Visible Spectral Range and Photopolymer Compositions Containing Same | COVESTRO DEUTSCHLAND AG (DE) | 2025-05-29 | — | — | US | disclosed |
| US-20250155845-A1 | Triarylalkyl Borate Salts as Coinitiators in NIR Photopolymer Compositions | COVESTRO DEUTSCHLAND AG (DE) | 2025-05-15 | — | — | US | disclosed |
| EP-3632892-B1 | METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2024-07-31 | — | — | EP | disclosed |
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4308227-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023235548-A1 | SQUARAMIDE DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| WO-2023156482-A1 | THERMOSTABLE PHOTOPOLYMERS IN THE VISIBLE SPECTRAL RANGE AND PHOTOPOLYMER COMPOSITIONS CONTAINING SAME | COVESTRO DEUTSCHLAND AG (DE) | 2023-08-24 | — | — | WO | disclosed |
| EP-0930296-B1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2002-07-24 | — | — | EP | disclosed |
| EP-1053990-A2 | A method of producing an aromatic ketone and an aromatic ketone composition containing it | TORAY INDUSTRIES, INC. (JP) | 2000-11-22 | — | — | EP | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5985920-A | COMPOUNDS FOR TREATMENT OF VISION DEFECTS SUCH AS GLAUCOMA | ASAHI GLASS COMPANY LTD. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0930296-A1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS COMPANY LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5886035-A | PREVENTIVE AND THERAPEUTICAL MEDICINE FOR EYE DISEASE | ASAHI GLASS COMPANY LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0850926-A2 | Difluoroprostaglandin derivatives and their use | ASAHI GLASS COMPANY LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0815105-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINONE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | HOECHST MARION ROUSSEL, INC. (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028441-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINONE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | HOECHST MARION ROUSSEL, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-3931218-A | HYPOGLYCEMIC ANTIRESERPINE, ANTIULCER, OGENIC, ANTIARRHYTHMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | TAAR1 4498/4885AOC3 3054/4885PNMT 3593/4885 |
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK4 | TAAR1 3610/4885AOC3 1657/4885PNMT 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.